Novo Nordisk A/S – Share repurchase programme
Novo Nordisk A/S – Share repurchase programme
Read the original here:
Novo Nordisk A/S – Share repurchase programme
Genmab and Seattle Genetics Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual…
Media Release COPENHAGEN, Denmark and BOTHELL, Wash., 21 September 2020
Simplify Medical Receives FDA Approval for 1-Level Simplify Disc PMA
Simplify Disc overall success rate of 93.0% was superior to the ACDF control Simplify Disc overall success rate of 93.0% was superior to the ACDF control
View original post here:
Simplify Medical Receives FDA Approval for 1-Level Simplify Disc PMA
RECORDATI LICENSES AN INNOVATIVE EPINEPHRINE NASAL SPRAY IN DEVELOPMENT FOR ANAPHYLAXIS PREVENTION
RECORDATI LICENSES AN INNOVATIVE EPINEPHRINE NASAL SPRAY IN DEVELOPMENT FOR ANAPHYLAXIS PREVENTION
Here is the original post:
RECORDATI LICENSES AN INNOVATIVE EPINEPHRINE NASAL SPRAY IN DEVELOPMENT FOR ANAPHYLAXIS PREVENTION
VBL Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
TEL AVIV, Israel, Sept. 21, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announces that Prof. Dror Harats, M.D., Chief Executive Officer, will provide a corporate overview, at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit being held virtually September 21-23, 2020.
Here is the original post:
VBL Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Apellis Announces Late-Breaking Presentation of Targeted C3 Therapy Pegcetacoplan in Patients with Geographic Atrophy (GA) at EURETINA 2020
WALTHAM, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that a post hoc analysis of the Phase 2 FILLY study investigating intravitreal pegcetacoplan (APL-2) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) has been accepted as a late-breaking oral presentation by EURETINA 2020 Virtual.
Strong operating performance continues as Golden Leaf Holdings expects to report a successive record revenue quarter and positive cash flow from…
Q3 2020 Selected Year-to-date results Q3 2020 Selected Year-to-date results
View original post here:
Strong operating performance continues as Golden Leaf Holdings expects to report a successive record revenue quarter and positive cash flow from...
Eton Pharmaceuticals Announces FDA Approval of Orphan Drug ALKINDI® SPRINKLE (hydrocortisone) as Replacement Therapy in Pediatric Patients with…
-ALKINDI SPRINKLE is the first and only FDA-approved granular hydrocortisone formulation for adrenocortical insufficiency specifically designed for children
See the article here:
Eton Pharmaceuticals Announces FDA Approval of Orphan Drug ALKINDI® SPRINKLE (hydrocortisone) as Replacement Therapy in Pediatric Patients with...
Kiadis announces results for the six months ended June 30, 2020 and significant progress made to date in 2020 in all development programs
Amsterdam, The Netherlands, September 30, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company focused on the development of innovative natural killer (NK) cell-based medicines for the treatment of life-threatening diseases, today announces its unaudited interim results for the six months ended June 30, 2020, which have been prepared in accordance with International Financial Reporting Standards (IFRS) as adopted by the European Union.
Go here to read the rest:
Kiadis announces results for the six months ended June 30, 2020 and significant progress made to date in 2020 in all development programs
Stabilitech Biopharma announces name change to iosBio
PRESS RELEASE
See more here:
Stabilitech Biopharma announces name change to iosBio